Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc.

NNASDAQ:BDTX
1.53
USD
+0.06
(+4.08%)
-0.77EPS
108.33MMarket Cap
Mar 24Next Earn
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
(Nasdaq Stock Market)

Recent

price

1.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
1.23
- -
Revenue per Share
-0.64
-0.64
-1.08
-2.04
-3.47
-2.52
-1.88
-1.27
0.39
-0.77
Basic EPS, GAAP
-0.34
-0.61
-0.76
-1.59
-2.84
-2.35
-1.52
-1.13
0.52
-0.58
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.59
-2.34
-1.44
8.53
5.41
3.18
2.26
1.47
1.96
1.53
Book Value per Share
-0.59
-2.34
-1.44
8.53
5.41
3.18
2.26
1.47
1.96
1.53
Tangible Book Value per Share
7
14
33
33
36
36
44
55
57
57
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
70
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
28.39
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
Depreciation Expense
-5
-9
-35
-67
-126
-91
-82
-70
22
-44
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
31.95
- -
Profit Margin (%)
6
49
151
305
192
112
114
81
117
91
Working Capital
- -
- -
- -
8
28
25
22
19
15
12
LT Debt
-7
-16
-47
308
196
116
117
83
112
88
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
10.59
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
18.92
- -
Return on Capital (%)
- -
- -
- -
- -
-49.87
-58.52
-70.94
-69.67
22.88
-41.14
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
4
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
14
13
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
57
57
Market Capitalization
122
106
108

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
123
115
107
Cash, Cash Equivalents & STI
118
111
102
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
15
16
15
Payables & Accruals
11
12
11
ST Debt
4
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-14.06%
34.73%
Free Cash Flow
- -
-19.26%
-147.53%
Net Income, GAAP
- -
-19.56%
-132.1%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
70
- -
- -
- -
70
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.35
-0.36
-0.28
-0.28
-1.27
2025
1
-0.19
-0.15
-0.26
0.39
2026
-0.16
-0.17
-0.17
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Black Diamond Therapeutics, Inc. (BDTX), a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies targeting families of oncogenic mutations in patients with genetically defined solid tumors; its proprietary MAP (Mutation-Allostery-Pharmacology) drug discovery engine enables the design of brain-penetrant small-molecule inhibitors that address intrinsic and acquired resistance while minimizing wild-type toxicities. The company's lead product candidate, BDTX-1535 (silevertinib), a fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, advances in a Phase 2 trial for EGFR-mutant non-small cell lung cancer (NSCLC), including first-line patients where it demonstrates a 60% objective response rate and 86% central nervous system response rate, and a Phase 1 trial for glioblastoma with a randomized Phase 2 trial planned for 2026; BDTX-4933, a RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors, progresses in Phase 1 development; BDTX-4876, a selective FGFR2/3 MasterKey inhibitor, remains in preclinical stages. Founded in 2014 and headquartered at One Main Street, 14th Floor, Cambridge, Massachusetts, the company operates primarily in the United States with a global focus on precision oncology for patients with brain-penetrant needs in CNS disease and resistant cancers. In March 2025, Black Diamond entered a global licensing agreement with Servier for BDTX-4933, securing a $70 million upfront payment and up to $710 million in milestones to fund operations into Q4 2026; the deal reported as a $56.5 million net income in Q1 2025, reversing prior losses, while recent pipeline prioritization advances key catalysts like Phase 2 NSCLC data disclosures.

Company News

  • Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

  • Why Is Black Diamond Therapeutics Stock Soaring Tuesday?

  • Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript

  • Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update

  • Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy

  • Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)

  • Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)

  • Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

  • Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

  • BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

  • Black Diamond Stock Outlook After Q1 Beat and Cash Runway

  • BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

  • What's Going On With Black Diamond Therapeutics Stock Tuesday?

  • BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

  • Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

  • Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

  • Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

  • Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

  • BDTX Shares Gain 11% in a Week: Here's What You Should Know